SEP 21, 2017 02:43 PM PDT
Leveraging Probiotics to Fight Colorectal Cancer
WRITTEN BY: Xuan Pham
3 10 474

Image credit: Pixabay.com

The gut microbiome is increasingly recognized as a vital player in the development of colon cancer. But good bacteria, scientists say, can help us turn the tide against the insidious disease.

The microbiome is a specialized collection of bacteria residing in specialized niches of the body. Mostly famous for their existence in the human gut, these communities of microorganisms have been known to influence processes like digestion and immune responses. The gut microbiota, in particular, has been linked to inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis. In turn, these diseases increase the risk for colon cancer.

Colon cancer, also known as colon cancer or bowel cancer, is the third most common non-skin cancer type in the world. The cancer usually begins as small, benign lumps of cells that form polyps in the colon. Without proper removal, these polyps can turn cancerous and cause symptoms such as abdominal pain, rectal bleeding, weakness, and fatigue. According to a recent report, the incidence of colorectal cancer is expected to increase by 60% to more than 2.2 million new cases and 1.1 million deaths by 2030.

Could good bacteria, AKA probiotics, lower the risk for colon cancer?

In the current study, scientists at the Baylor College of Medicine in Houston, Texas, focused on the effects of Lactobacillus reuteri, which is a probiotic naturally found in the guts of mammals.

The team injected L. reuteri into mice that were deficient in an enzyme called histidine decarboxylase (HDC). Without HDC, these mice are much more susceptible to develop colorectal cancer. By contrast, one of the roles of L. reuteri involves producing the enzyme HDC.

In mice treated with the probiotic, the team found less tumors, and the ones they did find were smaller in size. By contrast, animals that received the placebo treatment had more numerous and larger tumors. The results suggest the probiotic L. reuteri has protective effects against colorectal tumor formation.

"Our results suggest a significant role for histamine in the suppression of chronic intestinal inflammation and colorectal tumorigenesis [tumor formation]," says Dr. James Versalovic, a professor of pathology and immunology at Baylor, and the study’s lead author. "We have also shown that cells, both microbial and mammalian, can share metabolites or chemical compounds that together promote human health and prevent disease."

“We are on the cusp of harnessing advances in microbiome science to facilitate diagnosis and treatment of human disease. By simply introducing microbes that provide missing life substances, we can reduce the risk of cancer and supplement diet-based cancer prevention strategies,” he added.

Additional sources: MNT

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
FEB 15, 2018
Immunology
FEB 15, 2018
Cancer-Killing Virus Collaborates with the Human Immune System
An unlikely collaboration, a virus and the human immune system, is working to address a common enemy: cancer. From the University of California San Francis
APR 10, 2018
Cancer
APR 10, 2018
Gastric Cancer Screening Tool Using Serum Biomarkers Being Studied in South Korea
A group in South Korea are conducting a clinical trial to evaluate a diagnostic screening tool for gastric cancer using serum biomarkers and the ideal interval for screening endoscopies.
MAY 15, 2018
Cancer
MAY 15, 2018
May Is Skin Cancer Awareness Month...Are You Protected?
May is skin cancer awareness month. Are you armed with the tools and information you need to prevent, identify, and be informed about skin cancer?
JUN 07, 2018
Clinical & Molecular DX
JUN 07, 2018
Digital Screening Vital for Detecting Breast Cancer
A combination of two digital techniques could be the best way to diagnose breast cancer. In a new study, scientists show how combining a technique called t
JUN 12, 2018
Cancer
JUN 12, 2018
CD44 Insights & Cancer Influence
CD44 is a known cell surface protein involved in numerous interactions; it is overexpressed in cancerous tissue and its isoforms are being investigated as targets for cancer immunotherapy
JUN 16, 2018
Clinical & Molecular DX
JUN 16, 2018
Nanoparticles Deliver "Theranostics" for Cancer Patients
New technology combing therapeutic agents and diagnostics (theranostics) can be used to deliver drugs to cancer cells. From the Moscow Institute of Physics
Loading Comments...